{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T04:20:57Z","timestamp":1788495657740,"version":"build-2803163510"},"reference-count":53,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","geriatric.theclinics.com","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Geriatric Medicine"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.cger.2022.05.010","type":"journal-article","created":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T08:57:07Z","timestamp":1663059427000},"page":"705-714","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Polypharmacy in Oncology"],"prefix":"10.1016","volume":"38","author":[{"given":"Justin J.","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asal M.","family":"Azizoddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Maranzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narine","family":"Sargsyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.cger.2022.05.010_bib1","first-page":"32","article-title":"Polypharmacy: evaluating risks and deprescribing","volume":"100","author":"Halli-Tierney","year":"2019","journal-title":"Am Fam Physician"},{"issue":"1","key":"10.1016\/j.cger.2022.05.010_bib2","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s12094-020-02386-8","article-title":"Breast cancer, placing drug interactions in the spotlight: is polypharmacy the cause of everything?","volume":"23","author":"Dom\u00ednguez-Alonso","year":"2021","journal-title":"Clin Transl Oncol"},{"issue":"1","key":"10.1016\/j.cger.2022.05.010_bib3","doi-asserted-by":"crossref","first-page":"e94","DOI":"10.1634\/theoncologist.2019-0406","article-title":"Associations of polypharmacy and inappropriate medications with adverse outcomes in older adults with cancer: a systematic review and meta-analysis","volume":"25","author":"Mohamed","year":"2020","journal-title":"Oncologist"},{"issue":"5","key":"10.1016\/j.cger.2022.05.010_bib4","doi-asserted-by":"crossref","first-page":"e451","DOI":"10.1200\/JOP.2016.018317","article-title":"Polypharmacy and adherence to adjuvant endocrine therapy for breast cancer","volume":"13","author":"Calip","year":"2017","journal-title":"J\u00a0Oncol Pract"},{"issue":"1","key":"10.1016\/j.cger.2022.05.010_bib5","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1089\/jwh.2020.8493","article-title":"The use and concurrent use of side effect controlling medications among women on aromatase inhibitors","volume":"30","author":"Farkas","year":"2021","journal-title":"J\u00a0Womens Health (Larchmt)"},{"issue":"3","key":"10.1016\/j.cger.2022.05.010_bib6","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1046\/j.1523-5394.1999.07305.x","article-title":"Complementary therapy use among older cancer patients","volume":"7","author":"Wyatt","year":"1999","journal-title":"Cancer Pract"},{"issue":"3","key":"10.1016\/j.cger.2022.05.010_bib7","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s12282-019-01040-8","article-title":"Comorbidity and polypharmacy in patients with breast cancer","volume":"27","author":"Topalo\u011flu","year":"2020","journal-title":"Breast Cancer"},{"issue":"25","key":"10.1016\/j.cger.2022.05.010_bib8","doi-asserted-by":"crossref","first-page":"3837","DOI":"10.1200\/JCO.2007.11.4850","article-title":"Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer","volume":"25","author":"Lim","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"Suppl 7","key":"10.1016\/j.cger.2022.05.010_bib9","doi-asserted-by":"crossref","first-page":"vii36","DOI":"10.1093\/annonc\/mdt266","article-title":"Polypharmacy and the management of the older cancer patient","volume":"24","author":"Balducci","year":"2013","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.cger.2022.05.010_bib10","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.4088\/JCP.08r04856blu","article-title":"Interactions between tamoxifen and antidepressants via cytochrome P450 2D6","volume":"70","author":"Desmarais","year":"2009","journal-title":"J\u00a0Clin Psychiatry"},{"issue":"5","key":"10.1016\/j.cger.2022.05.010_bib11","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1517\/17425255.2015.1037277","article-title":"Effect of age on drug metabolism in women with breast cancer","volume":"11","author":"Singh","year":"2015","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"5","key":"10.1016\/j.cger.2022.05.010_bib12","first-page":"555","article-title":"Real-world direct health care costs associated with psychotropic polypharmacy among adults with common cancer types in the United States","volume":"25","author":"Vyas","year":"2019","journal-title":"J\u00a0Manag Care Spec Pharm"},{"issue":"1","key":"10.1016\/j.cger.2022.05.010_bib13","first-page":"7","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"10.1016\/j.cger.2022.05.010_bib14","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1053\/j.seminoncol.2016.02.009","article-title":"Prognostic factors and risk stratification in chronic lymphocytic leukemia","volume":"43","author":"Parikh","year":"2016","journal-title":"Semin Oncol"},{"issue":"25","key":"10.1016\/j.cger.2022.05.010_bib15","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cger.2022.05.010_bib16","doi-asserted-by":"crossref","first-page":"630942","DOI":"10.3389\/fcell.2021.630942","article-title":"Comparative analysis of BTK inhibitors and mechanisms underlying adverse effects","volume":"9","author":"Estupi\u00f1\u00e1n","year":"2021","journal-title":"Front Cell Dev Biol"},{"issue":"31","key":"10.1016\/j.cger.2022.05.010_bib17","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.21.01210","article-title":"Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial","volume":"39","author":"Byrd","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.cger.2022.05.010_bib18","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.clml.2018.07.287","article-title":"Risk of major bleeding with ibrutinib","volume":"18","author":"Mock","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"23","key":"10.1016\/j.cger.2022.05.010_bib19","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1182\/blood.2021011568","article-title":"Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia","volume":"137","author":"Herishanu","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.cger.2022.05.010_bib20","series-title":"Cancer facts & figures 2021","year":"2021"},{"issue":"8","key":"10.1016\/j.cger.2022.05.010_bib21","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1111\/jgs.12942","article-title":"Polypharmacy and potentially inappropriate medication use in older adults with cancer undergoing chemotherapy: effect on chemotherapy-related toxicity and hospitalization during treatment","volume":"62","author":"Maggiore","year":"2014","journal-title":"J\u00a0Am Geriatr Soc"},{"issue":"8, Supplement 1","key":"10.1016\/j.cger.2022.05.010_bib22","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1016\/S1879-4068(21)00446-X","article-title":"SIOG2021-0124 - association of polypharmacy with colorectal cancer survival among older patients","volume":"12","author":"Chen","year":"2021","journal-title":"J\u00a0Geriatr Oncol"},{"issue":"10","key":"10.1016\/j.cger.2022.05.010_bib23","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.3390\/cancers12102724","article-title":"Impact of polypharmacy for chronic ailments in colon cancer patients: a review focused on drug repurposing","volume":"12","author":"Giampieri","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.cger.2022.05.010_bib24","doi-asserted-by":"crossref","first-page":"C176","DOI":"10.1152\/ajpcell.00196.2016","article-title":"Aspirin therapy reduces the ability of platelets to promote colon and pancreatic cancer cell proliferation: implications for the oncoprotein c-MYC","volume":"312","author":"Mitrugno","year":"2017","journal-title":"Am J Physiol Cell Physiol"},{"issue":"1","key":"10.1016\/j.cger.2022.05.010_bib25","doi-asserted-by":"crossref","first-page":"611","DOI":"10.18632\/aging.102644","article-title":"Aspirin enhances the sensitivity of colon cancer cells to cisplatin by abrogating the binding of NF-\u03baB to the COX-2 promoter","volume":"12","author":"Jiang","year":"2020","journal-title":"Aging (Albany NY)"},{"issue":"8","key":"10.1016\/j.cger.2022.05.010_bib26","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.3390\/cancers11081174","article-title":"Use of antibiotics and risk of cancer: a systematic review and meta-analysis of observational studies","volume":"11","author":"Petrelli","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"9","key":"10.1016\/j.cger.2022.05.010_bib27","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1007\/s12094-020-02301-1","article-title":"Outcomes of metastatic colorectal cancer patients in relationship to prior and concurrent antibiotics use; individual patient data analysis of three clinical trials","volume":"22","author":"Abdel-Rahman","year":"2020","journal-title":"Clin Transl Oncol"},{"issue":"1","key":"10.1016\/j.cger.2022.05.010_bib28","doi-asserted-by":"crossref","first-page":"11","DOI":"10.4251\/wjgo.v6.i1.11","article-title":"Antidepressant fluoxetine and its potential against colon tumors","volume":"6","author":"Stopper","year":"2014","journal-title":"World J Gastrointest Oncol"},{"issue":"2","key":"10.1016\/j.cger.2022.05.010_bib29","doi-asserted-by":"crossref","first-page":"e975080","DOI":"10.4161\/23723556.2014.975080","article-title":"Discovery and validation of the antimetastatic activity of citalopram in colorectal cancer","volume":"2","author":"Iskar","year":"2015","journal-title":"Mol Cell Oncol"},{"issue":"7","key":"10.1016\/j.cger.2022.05.010_bib30","doi-asserted-by":"crossref","first-page":"e38886","DOI":"10.1371\/journal.pone.0038886","article-title":"Mirtazapine inhibits tumor growth via immune response and serotonergic system","volume":"7","author":"Fang","year":"2012","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.cger.2022.05.010_bib31","doi-asserted-by":"crossref","first-page":"E1170","DOI":"10.1210\/jc.2012-1162","article-title":"Oral insulin secretagogues, insulin, and cancer risk in type 2 diabetes mellitus","volume":"97","author":"Chang","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.cger.2022.05.010_bib32","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1158\/2159-8290.CD-12-0263","article-title":"Investigating metformin for cancer prevention and treatment: the end of the beginning","volume":"2","author":"Pollak","year":"2012","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.cger.2022.05.010_bib33","doi-asserted-by":"crossref","DOI":"10.3390\/ph14010067","article-title":"Drug-Drug interactions and pharmacogenomic evaluation in colorectal cancer patients: the new drug-PIN(\u00ae) system comprehensive approach","volume":"14","author":"Roberto","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"issue":"4","key":"10.1016\/j.cger.2022.05.010_bib35","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/jgs.15767","article-title":"American geriatrics society 2019 updated AGS Beers Criteria\u00ae for potentially inappropriate medication use in older adults","volume":"67","year":"2019","journal-title":"J\u00a0Am Geriatr Soc"},{"issue":"1","key":"10.1016\/j.cger.2022.05.010_bib36","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1158\/1055-9965.EPI-17-0523","article-title":"Potential medication-related problems in older breast, colon, and lung cancer patients in the United States","volume":"27","author":"Lund","year":"2018","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"10","key":"10.1016\/j.cger.2022.05.010_bib37","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1007\/s00432-020-03252-4","article-title":"Polypharmacy as a prognostic factor in older patients with advanced non-small-cell lung cancer treated with anti-PD-1\/PD-L1 antibody-based immunotherapy","volume":"146","author":"Hakozaki","year":"2020","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"issue":"15","key":"10.1016\/j.cger.2022.05.010_bib38","article-title":"Anti-dementia and anti-hyperlipidemic medication use at end of life in elderly lung cancer patients: analysis of SEER-Medicare data","volume":"35","author":"Kim","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.cger.2022.05.010_bib39","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.jgo.2020.03.001","article-title":"Relationship between polypharmacy and inpatient hospitalization among older adults with cancer treated with intravenous chemotherapy","volume":"11","author":"Lu-Yao","year":"2020","journal-title":"J\u00a0Geriatr Oncol"},{"key":"10.1016\/j.cger.2022.05.010_bib40","doi-asserted-by":"crossref","first-page":"764","DOI":"10.3332\/ecancer.2017.764","article-title":"Systemic anticancer therapy (SACT) for lung cancer and its potential for interactions with other medicines","volume":"11","author":"Panchal","year":"2017","journal-title":"Ecancermedicalscience"},{"issue":"2","key":"10.1016\/j.cger.2022.05.010_bib41","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1056\/NEJMoa050736","article-title":"Erlotinib in lung cancer \u2014 molecular and clinical predictors of outcome","volume":"353","author":"Tsao","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.cger.2022.05.010_bib42","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non\u2013small-cell lung cancer","volume":"378","author":"Soria","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.cger.2022.05.010_bib43","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/clpt.2012.73","article-title":"Drug absorption interactions between oral targeted anticancer agents and PPIs: is pH-dependent solubility the Achilles heel of targeted therapy?","volume":"92","author":"Budha","year":"2012","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"10.1016\/j.cger.2022.05.010_bib44","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1002\/cncr.31917","article-title":"The concomitant use of tyrosine kinase inhibitors and proton pump inhibitors: prevalence, predictors, and impact on survival and discontinuation of therapy in older adults with cancer","volume":"125","author":"Sharma","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.cger.2022.05.010_bib45","series-title":"Facts & figures 2022","year":"2022"},{"issue":"1","key":"10.1016\/j.cger.2022.05.010_bib47","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.cger.2015.08.001","article-title":"Management of prostate cancer in the elderly","volume":"32","author":"Tay","year":"2016","journal-title":"Clin Geriatr Med"},{"issue":"12","key":"10.1016\/j.cger.2022.05.010_bib48","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1002\/cncr.26392","article-title":"Prostate cancer in the elderly: frequency of advanced disease at presentation and disease-specific mortality","volume":"118","author":"Scosyrev","year":"2012","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.cger.2022.05.010_bib49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/dmd.121.000401","article-title":"Pharmacokinetic drug-drug interactions with drugs approved by the us food and drug administration in 2020: mechanistic understanding and clinical recommendations","volume":"50","author":"Yu","year":"2022","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.cger.2022.05.010_bib50","unstructured":"NCCN Clinical Practice Guidelines in Oncology \u2013 Prostate Cancer. Version 1.2022. Accessed."},{"issue":"2","key":"10.1016\/j.cger.2022.05.010_bib51","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1016\/j.clgc.2019.05.016","article-title":"Drug-drug interactions in prostate cancer treatment","volume":"18","author":"Hebenstreit","year":"2020","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.cger.2022.05.010_bib52","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ctrv.2017.03.001","article-title":"The role of drug-drug interactions in prostate cancer treatment: focus on abiraterone acetate\/prednisone and enzalutamide","volume":"55","author":"Del Re","year":"2017","journal-title":"Cancer Treat Rev"},{"issue":"12","key":"10.1016\/j.cger.2022.05.010_bib53","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1080\/17425255.2021.2027908","article-title":"Potential and real drug interactions in patients treated with abiraterone or enzalutamide in clinical practice","volume":"17","author":"Vicente-Valor","year":"2021","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"7_suppl","key":"10.1016\/j.cger.2022.05.010_bib54","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1200\/JCO.2019.37.7_suppl.297","article-title":"Drug-drug interaction (DDI) of darolutamide with cytochrome P450 (CYP) and P-glycoprotein (P-gp) substrates: results from clinical and in\u00a0vitro studies","volume":"37","author":"Zurth","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.cger.2022.05.010_bib55","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s11523-019-00674-0","article-title":"Evaluation of clinically relevant drug-drug interactions and population pharmacokinetics of darolutamide in patients with nonmetastatic castration-resistant prostate cancer: results of pre-specified and post hoc analyses of the phase III ARAMIS trial","volume":"14","author":"Shore","year":"2019","journal-title":"Target Oncol"}],"container-title":["Clinics in Geriatric Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749069022000325?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749069022000325?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:58:09Z","timestamp":1760061489000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0749069022000325"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":53,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S0749069022000325"],"URL":"https:\/\/doi.org\/10.1016\/j.cger.2022.05.010","relation":{},"ISSN":["0749-0690"],"issn-type":[{"value":"0749-0690","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Polypharmacy in Oncology","name":"articletitle","label":"Article Title"},{"value":"Clinics in Geriatric Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cger.2022.05.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}